Monika Jermann
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Jermann M, Bauer J, Rhyner K, Egli F, Morant R, Gillessen Sommer S, Jörger M, Cerny T, Salzberg M, Stahel R, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology 2006; 57:533-9.
Apr 1, 2006A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Apr 1, 2006Cancer chemotherapy and pharmacology 2006; 57:533-9
Jermann Monika, Bauer Jean A, Rhyner Kaspar, Egli Fritz, Morant Rudolf, Gillessen Sommer Silke, Jörger Markus, Cerny Thomas, Salzberg Marc, Stahel Rolf A, Pless Miklos
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy
Gautschi O, Stahel R, Betticher D, Jörger M, Weder W, Ratschiller D, Chassé E, Marx A, Jermann M, Huegli B, Bigosch C, Ziegler A. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:4157-64.
Oct 15, 2004Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy
Oct 15, 2004Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:4157-64
Gautschi Oliver, Stahel Rolf A, Betticher Daniel C, Jörger Markus, Weder Walter, Ratschiller Daniel, Chassé Eveline, Marx Arthur, Jermann Monika, Huegli Barbara, Bigosch Colette, Ziegler Annemarie